Project Grant R37AI203695
Award Date 8/18/26
Completion Date 7/31/31
Dollars Obligated $791K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $427,626 to The Washington University on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify host factors that mediate nuclear retention of unspliced and partially spliced HIV-1 transcripts. The project will determine mechanisms by which intron-containing HIV-1 RNA molecules remain in the nucleus, contrasting with fully spliced viral messenger RNA that readily accesses host nuclear...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology (MIT) $553,136 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research visualizing HIV-1 capsid passage through the nuclear pore complex. The funded work addresses how HIV-1 traverses the nuclear pore complex during viral entry into the cell nucleus, a critical stage in the infection process preceding uncoating, reverse transcription, and...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $427,623 to The Washington University on February 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research dissecting how HIV-induced immunometabolic perturbation impairs tuberculosis control in people living with HIV despite effective antiretroviral therapy and viral suppression. The research...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $777,756 on June 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct Research on End-User Acceptability and Long-Term Impacts of HIV Cure Strategies (REALISE). The project delivers three integrated research aims. Aim 1 conducts qualitative interviews with approximately 30 researchers and developers to define plausible 10–20-year HIV cure and long-acting...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $100,228 on February 18, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Type: Project Grant). The recipient will conduct structural and biochemical determination of the HIV-1 capsid nucleoporin 214 (NUP214) interaction. The work addresses the mechanism by which HIV-1 capsid cores traverse the nuclear pore complex to deliver viral genome and enable integration; it...
- The National Institute of Allergy and Infectious Diseases awarded George Washington University $781,999 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decipher mechanisms regulating the HLA-F and KIR3DS1 interaction in natural killer cells and HIV pathogenesis. The project, titled "Deciphering the Role of HLA-F and KIR3DS1 on NK Function and HIV Pathogenesis," focuses on understanding how the interaction between the KIR3DS1 receptor on NK...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $149,190 on December 25, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel antiviral compounds targeting lenacapavir-resistant HIV. The research will characterize three novel capsid effectors designed to overcome resistance-associated mutations in HIV that render lenacapavir ineffective. The work comprises three aims: biochemical and biophysical assessment of each...
- The National Institute of Allergy and Infectious Diseases awarded Western University of Health Sciences $144,000 on June 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how HIV accessory proteins VPU and NEF target the IPS-1 adaptor protein, leading to its degradation and inhibition of type I interferon production. The research examines the mechanism by which HIV manipulates the interferon system to evade immune detection and persist in the host,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Utah $226,884 on January 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the role of HIV-1 integrase in viral maturation. The award funds structural biology and biophysical research investigating how HIV-1 integrase acts as a physical bridge between viral genomic RNA and the assembling capsid during maturation. The research employs complementary structural biology...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $144,196 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the functional role and biophysical characterization of the disordered N-terminal domain from the Borna disease virus phosphoprotein. The project, led by Principal Investigator Madison A. Stringer, combines biochemical and biophysical techniques to characterize the N-terminal...